TY - JOUR ID - 29944 TI - Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014 JO - Iranian Journal of Pathology JA - IJP LA - en SN - 1735-5303 AU - Moazed, Vahid AU - Jafari, Elham AU - Kalantari khandani, Behjat AU - Nemati, Ali AU - benrazavi, seyedamir AD - Hematology and Oncology Division, Dept of Internal medicine, Afzalipour Kerman Medical Science University, Kerman, Iran AD - Pathology and Stem Cells Research Center, Dept of Pathology, Afzalipour Kerman Medical Science University, Kerman, Iran AD - Dept. of Internal Medicine, Afzalipour Kerman Medical Science University, Kerman, Iran Y1 - 2018 PY - 2018 VL - 13 IS - 1 SP - 71 EP - 77 KW - Neoadjuvant Therapy KW - Ki 67 KW - Breast cancer KW - Prognosis DO - 10.30699/ijp.13.1.71 N2 - Background and objective:Breast cancer is the most common malignancy among women. The Neoadjuvant chemotherapy is the treatment of choice for non-operable tumors. The Ki67 is a proliferation marker that can be used to predict the therapeutic response to chemotherapy and the patients' prognosis. Methods: This retrospective study was carried out on 55 consecutive patients with breast cancer referred to a Training Tertiary Healthcare Center in Kerman, Iran since 2009 to 2014. After diagnostic approval, the tissue samples of patients were examined for estrogen and progesterone receptors, ki67 and HER2-neu markers by using immunohistochemical staining. Then the patients were treated with 6 cycles of Neoadjuvant chemotherapy regimens by Doxorubicin and Taxans or 4 chemotherapy cycles, containing Anthracycline and Cyclophosphamide and 4 cycles of Paclitaxel. After mastectomy, their samples were reexamined for ki67 again and classified into three groups (low: ki67<15%), medium (Ki67 = 16-30%) and high (Ki67> 30%). Results: Before chemotherapy, 54.5% of the patients had high expression of Ki67. But after chemotherapy, 52.7 of the patients had complete therapeutic response showing that the Ki67 level was reduced significantly (P=0.003). Conclusion: Before and after Neoadjuvant chemotherapy, Ki67 measurements may be used as a predictive marker of therapeutic response. UR - https://ijp.iranpath.org/article_29944.html L1 - https://ijp.iranpath.org/article_29944_5c2fba9243efb69816ca74a185acec5b.pdf ER -